TILLIT has added five new funds to its platform including a biotech strategy and a UK investment trust, creating a universe of over 100 strategies.
The additions include the ARGA Global Equity fund, Polar Capital Biotechnology, Pzena US Large Cap Value, Rockwood Strategic, and the Royal London Sustainable World trust.
Sheridan Admans (pictured), head of fund selection at TILLIT, said: “New additions to our platform are aimed at diversifying and extending the breadth of opportunities for investors to discover on the TILLIT platform. We have added more funds that have a bias towards value and deep value, a style of investing that has become more predominant in recent times. Additionally, we have added funds with a focus on healthcare, sustainability, and a spicier investment trust focused on unlocking hidden value.”
See also: Titan launches multi-asset fund range
The Rockwood Strategic investment trust has a focus on UK-listed small and micro caps, looking for companies that are cash-generative but have run into setbacks affecting their valuation. The trust has a share price total return of 153.8% in the past five years, and trades at a 2.72% discount to its net asset value, according to the Association of Investment Companies.
TILLIT’s healthcare addition comes through the Polar Capital Biotechnology fund, which is focused on companies developing new drugs, diagnostics and research tools. In the past five years, it has returned 89.97%, compared to a sector average 31.17%, according to FE fundinfo.
This story was written by our sister title, Portfolio Adviser
